急性缺血性脑卒中的临床治疗研究进展  

Research progress in clinical treatment of acute ischemic stroke

作　　者：申青仙 张赛 涂悦 王振国 刘洋 Shen Qingxian;Zhang Sai;Tu Yue;Wang Zhenguo;Liu Yang(The Second Department of Neurology,Featured Medical Center of the Chinese People's Arrrwd Police Force,Tianjin 300162,China;Brain Centery Featured Medical Center of the Chinese People's Armed Police Forces,Tianjin 300162,China;Department of Neurology,Minhang District Central Hospital,Shanghai 201100,China)

机构地区：[1]中国人民武装警察部队特色医学中心神经内二科,天津300162 [2]中国人民武装警察部队特色医学中心脑科中心,天津300162 [3]上海市闵行区中心医院神经内科,201100

出　　处：《中国医药》2020年第4期633-636,共4页China Medicine

基　　金：国家自然科学基金(31200809);天津市科技计划(16ZXHLSY00120)。

摘　　要：脑卒中是世界范围内导致死亡和严重残疾的重要疾病之一,其中缺血性脑卒中占87%,而急性缺血性脑卒中患者1年内的病死率高达10%,致残率也高达20%~25%,因此急性缺血性脑卒中患者的早期有效治疗至关重要。目前,组织型纤溶酶原激活物静脉溶栓治疗和血管内血栓切除术成为急性缺血性脑卒中的标准治疗方案,而急性缺血性脑卒中的其他治疗方法也是有效的辅助治疗。本文将对急性缺血性脑卒中的临床治疗研究进展进行综述。Stroke is one of the leading causes of death and disability worldwide,among which ischemic stroke accounts for 87%. The 1-year mortality rate of acute ischemic stroke is 10% and the disability rate is20%-25%. Therefore,early intervention for acute ischemic stroke is essential to improve the prognosis. Intravenous thrombolysis with tissue plasminogen activator and endovascular thrombectomy are the major standard treatments of acute ischemic stroke. Other adjuvant therapeutic measures have proven to be effective as well. This paper reviewed the research progress in clinical treatment of acute ischemic stroke.

关 键 词：急性缺血性脑卒中 静脉溶栓治疗 组织型纤溶酶原激活物 血管内血栓切除术 

分 类 号：R743.3[医药卫生—神经病学与精神病学]